Heron Therapeutics, Inc. (HRTX)
收市後：
- Zacks
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
- Insider Monkey
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript May 7, 2024 Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.0209, expectations were $-0.08. HRTX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My […]
- Zacks
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
